Tocilizumab for multirefractory adult-onset Stills disease
Unit of Rheumatology, R Ballanger Hospital, Aulnay sous Bois, France
Correspondence to:
Dr M De Bandt, Unit of Rheumatology, R Ballanger Hospital, Aulnay sous Bois, 93600, France; m.debandt@ch-aulnay.fr
Accepted 24 March 2008
| The first 150 words of the full text of this article appear below. |
Adult-onset Stills disease (AOSD) is a multisystemic inflammatory disease of unknown cause, characterised by daily spiking fever, rash, leucocytosis and arthritis. Cytokines such as interleukin (IL)1, 6 and 18, interferon
, tumour necrosis factor are thought to have a role in the pathogenesis of the disease.1 2 Treatments such as non-steroidal anti-inflammatory drugs, steroids, methotrexate (MTX), gold, azathioprine, leflunomide, ciclosporin and biological agents (tumour necrosis factor blockers, IL1 receptor antagonist or rituximab) can help in the management of patients, depending on presentation and disease course.3–5
We report on a young woman with refractory AOSD successfully treated with anti-IL6 receptor antibody (tocilizumab), whose efficacy has been shown in systemic onset juvenile idiopathic arthritis.
AOSD started in this patient when she was age 26. She had spiking fever, rash, arthritis, high leucocytes count, lymphadenopathy and splenomegaly, she was rheumatoid factor and antinuclear antibody negative. She was treated with non-steroidal anti-inflammatory drugs and steroids.
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
